Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 235Breast Neoplasms 233Prostatic Neoplasms 170Multiple Myeloma 151Neoplasms 134Colorectal Neoplasms 126Leukemia, Myeloid, Acute 121Lung Neoplasms 108Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 88Melanoma 86Lymphoma 82Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 76Ovarian Neoplasms 71Sarcoma 68Carcinoma, Renal Cell 64Recurrence 63Lymphoma, Large B-Cell, Diffuse 63Brain Neoplasms 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 57Lymphoma, Non-Hodgkin 56Stomach Neoplasms 54Leukemia, Lymphocytic, Chronic, B-Cell 54Endometrial Neoplasms 53Hematologic Neoplasms 52Urinary Bladder Neoplasms 50Small Cell Lung Carcinoma 49

Interventions

palbociclib 1Letrozole 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Estrogen Receptor-positive Breast Cancer × 90 days × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡